Karen joined Advent in 2020 and brings 30 years of industry experience in strategy and collaborations for pharmaceutical and biotechnology companies in the United States, Europe and China, including strategic collaborations and mergers & acquisitions.
Karen spent the first 20 years of her career with Bristol-Myers Squibb. She has since served as Chief Business Officer with PsiOxus Therapeutics and WindMil Therapeutics as well as Advent Portfolio companies Artax Biopharma and Aleta Biotherapeutics. Karen serves on the board of directors of PaxMedica, a clinical stage autism company.
Karen received her MBA from Columbia University and Bachelor of Science in Industrial Engineering from Lehigh University where she currently serves on the P.C Rossin School of Engineering Advisory Board.